UnitedHealth Group Incorporated’s UNH pharmacy benefit management arm, Optum Rx, rolled out an industry-first transparent pharmacy care model that shifts away from opaque pricing tied to drug makers’ list prices and prescription volume to a clear, fee-based structure for all its PBM clients. The plan discloses every fee, eliminates spread pricing and adds digital tools that show patients real-time costs and options before they fill a prescription, aiming for simpler, predictable pharmacy benefits.
This move tackles long-standing opacity in drug pricing that frustrates patients and employers, promising clearer costs and better control over pharmacy spend in a system under regulatory scrutiny. In today’s political climate, where lawmakers are pushing PBM transparency and drug cost reforms, UnitedHealth’s move positions it as proactive, potentially easing regulatory pressure and aligning with broader cost-reduction goals.
Financially, the new model could stabilize and grow PBM margins by reducing unpredictable spreads and strengthening client trust, potentially attracting more contracts. Optum Rx, one of the nation’s largest PBMs, saw an adjusted operating margin of 3.3% in the first quarter of 2026, down from 3.8% a year ago.
Clear pricing and consumer tools may also reduce churn and lower cost trends, supporting long-term revenue sustainability. In the first quarter of 2026, Optum Rx posted earnings of $1.2 billion, down from $1.3 billion a year ago, pressured by lower volumes tied to membership attrition at UHC. Still, Optum remains a key stabilizer for UnitedHealth as its insurance arm wrestles with elevated medical costs.
Peers Suffering From Rising Medical Costs Trend Too
UnitedHealth’s peers, including Centene Corporation CNC and Elevance Health, Inc. ELV, are also grappling with rising medical costs due to higher utilization trends. Nevertheless, the companies are managing the problem better now.
Centene witnessed its health benefits ratio decrease to 87.3% in the first quarter from 87.5% a year ago, thanks to rate and revenue increases, improving medical cost management and moderate flu costs. Meanwhile, Elevance Health’s benefit expense ratio increased to 86.8% from 86.4% a year ago, due to higher medical costs, partially offset by improved Medicare performance.
UnitedHealth’s Price Performance, Valuation and Estimates
Shares of UNH have gained 16.5% in the year-to-date period compared with the industry’s growth of 14.7%.
Image Source: Zacks Investment Research
From a valuation standpoint, UnitedHealth trades at a forward price-to-earnings ratio of 20.15, up from the industry average of 16.95. UNH carries a Value Score of B.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for UnitedHealth’s 2026 earnings is pegged at $18.25 per share, implying an 11.6% improvement from the year-ago period.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report
Centene Corporation (CNC) : Free Stock Analysis Report
Elevance Health, Inc. (ELV) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
